Search | Clinical Trials Finder

Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions: TAS6417; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more

Conditions: Cancer
Interventions: BBI608, Paclitaxel; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 17
States / cities: Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: Hospital-at-Home/HAH; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid, Thymic Cancer, Lung Cancer
Interventions: Proton Therapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancers
Interventions: Not listed
Lead sponsor: Everest Detection, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions: MRTX1133; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more

Conditions: Tumors Characterized by Genetic Abnormalities of ALK
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose; Drug · Other
Lead sponsor: Neelesh Sharma MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions: oblimersen sodium, carboplatin, etoposide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: talabostat mesylate, docetaxel; Drug
Lead sponsor: Point Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 96
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Anchorage, Alaska + 81 more

Conditions: Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions: WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique; Biological · Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: carboplatin, paclitaxel, sunitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 27
States / cities: Los Angeles, California • Newark, Delaware • Wilmington, Delaware + 17 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Inivata; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Fort Smith, Arkansas • Joplin, Missouri • Springfield, Missouri + 3 more

Conditions: Breast Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Lung Cancer
Interventions: stereotactic body radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: Rochester, New York • Houston, Texas

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions: ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non Small Cell Lung Cancer
Interventions: Radiation Therapy, Targeted TKI therapy; Device · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: High Risk Cancer, Lung Cancer
Interventions: Median LCS; Device
Lead sponsor: Median Technologies; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas

Conditions: Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diet Modification, Lung Cancer
Interventions: Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions: PEPRR, Pep-Pal; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 510 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Pharmacological Ascorbate for Lung Cancer

A Study of Hospital-at-Home for People Receiving Tarlatamab

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy

Tumor Specific Plasma DNA

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

Reducing Insulin, Growth Hormones, and Tumors

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.